Marc Beer is the co-founder and CEO of Renovia Incorporation. The MedTech company is based in Boston. Renovia Inc. specializes in developing diagnostic and therapeutic products for treating and managing pelvic floor disorders such as urinary incontinence. Their first product, Leva, was approved by the FDA in April 2018. Research shows that more than 250 million in the world are affected by pelvic floor disorders.
Recently, the company obtained $32 million in the Series B round plus $10 million in venture debt, totaling to $42 million. The company is set to continue creating more products for managing pelvic floor disorders. One of the companies that joined the Series B round includes the Longwood Fund, a firm that invests in healthcare companies. The Longwood Fund was also part of Series A funding. Other funders for the Series B include Ascension Ventures, Missouri and Perceptive Advisors, New York.
Renovia Inc. intends to use the funds to develop and test four more products for diagnosing and treating pelvic floor disorders. One of the four devices includes the second version of the Leva device. Marc Beer was pleased by the support the company received from its investors. In a statement, he thanked the healthcare investors who share the company’s vision of improving diagnostic and therapeutic methods for pelvic floor disorders.
Renovia Inc. aims to give better treatment options, impart knowledge of pelvic floor disorders, and ultimately provide affordable diagnostic and treatment options. Marc believes that the company can achieve its goals by combining the innovative and sensor technology with a digital platform that informs the clients of new treatment options.
Marc Beer has over two decades of experience in the development and commercialization of pharmaceuticals, biotechnology, diagnostics, and devices. He co-founded Renovia Inc. with Yolanda Lorie and Ramon Iglesias, MD in August 2016. The team successfully closed Series A funding with top healthcare investors.
Besides Renovia Inc., Marc has founded and co-founded other companies such as ViaCell, a biotech company that majored in collecting, preserving, and developing umbilical cord blood stem cells. Marc led the company from its inception to a robust organization. Under his leadership, ViaCell grew to an employee base of 300. The company went public and was later acquired by PerkinElmer.
While serving as the CEO of ViaCell, Mark Beer served at Erytech Pharma in the Board of Directors. Prior to founding ViaCell, Marc served at Genzyme, and he held various positions including the Vice President of Global Marketing where his roles included launching several products that address rare diseases.
Marc Beer also held various sales and marketing positions in the pharmaceutical and diagnostic sector of Abbott Laboratories. He also served on the BIO (Biotechnology Industry Association).
The incredible passion and prowess for Marc Beer in building companies are amazing. His go-getter attitude has enabled him to achieve so much in life. Learn more: https://www.crunchbase.com/person/marc-beer